Non-steroidal anti-inflammatory drugs use in clinical practice: new opportunities

Cover Page

Cite item

Full Text

Abstract

Non-steroidal anti-inflammatory drugs (NSAIDs) are considered safe and effective analgesics. These medications effectively reduce pain syndrome and suppress local inflammation but unfortunately may cause a wide range of adverse effects. Although there are 28 different NSAIDs registered in Russia (and many of them have dozens of generics), none of them can be considered ideal in terms of effectiveness and safety. It explains development of new drugs in this group. Nowadays tenoxicam is again included in clinical use in Russia. This medication is well known all over the world. Tenoxicam effectiveness and safety were acknowledged in many clinical trials. And its use in clinical practice for many years is the main test that the drug has successfully passed. Opportunities of tenoxicam therapeutic use were shown in patients with rheumatoid arthritis, ankylosing spondylitis and gout. It allows to successfully reduce pain in patients with most common rheumatic disorders such as osteoarthritis and non-specific back pain. Tenoxicam proved to be an effective component of combined perioperative anesthesia in surgical practice. It is also effective for pain relief in urgent situations such as acute injuries, toothache, renal or gallstone colic. Tenoxicam is administered once a day, it has different pharmacological forms and a favorable safety profile. Undoubtedly, tenoxicam inclusion in clinical practice increases opportunities of analgesic therapy in practical use for various medical professionals.

About the authors

A. E Karateev

V.A.Nasonova Research Institute of Rheumatology

Email: aekarat@yandex.ru
д-р мед. наук, зав. лаб. патофизиологии боли и полиморфизма скелетно-мышечных заболеваний 115522, Russian Federation, Moscow, Kashirskoe sh., d. 34A

References

  1. Каратеев А.Е., Насонов Е.Л., Ивашкин В.Т. и др. Рациональное использование нестероидных противовоспалительных препаратов. Клинические рекомендации. Научно-практическая ревматология. 2018; 56: 1-29. https://doi.org/10.14412/1995-4484-2018-1-29
  2. Makris U.E, Abrams R.C, Gurland B, Reid M.C. Management of persistent pain in the older patient: a clinical review. JAMA 2014; 312 (8): 825-36. doi: 10.1001/jama.2014.9405
  3. Hunter T.S, Robison C, Gerbino P.P. Emerging evidence in NSAID pharmacology: important considerations for product selection. Am J Manag Care 2015; 21 (Suppl. 7): S139-47.
  4. Xu S, Rouzer C.A, Marnett L.J. Oxicams, a class of nonsteroidal anti-inflammatory drugs and beyond. IUBMB Life 2014; 66 (12): 803-11. doi: 10.1002/iub.1334
  5. Díaz-González F, Sánchez-Madrid F. NSAIDs: learning new tricks from old drugs. Eur J Immunol 2015; 45 (3): 679-86. doi: 10.1002/eji.201445222
  6. Vecchio A.J, Malkowski M.G. The structural basis of endocannabinoid oxygenation by cyclooxygenase-2. J Biol Chem 2011; 286 (23): 20736-45. doi: 10.1074/jbc.M111.230367
  7. Vecchio A.J, Simmons D.M, Malkowski M.G. Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem 2010; 285 (29): 22152-63. doi: 10.1074/jbc.M110.119867
  8. Nilsen O.G. Clinical pharmacokinetics of tenoxicam. Clin Pharmacokinet 1994; 26 (1): 16-43.
  9. https://www.drugs.com/international/tenoxicam.html
  10. http://www.ema.europa.eu/docs/en_GB/document_library/Periodic_safety_update_single_assessment/2016/1..
  11. Lora M, Morisset S, Ménard H.A et al. Expression of recombinant human cyclooxygenase isoenzymes in transfected COS-7 cells in vitro and inhibition by tenoxicam, indomethacin and aspirin. Prostaglandins Leukot Essent Fatty Acids 1997; 56 (5): 361-7.
  12. Van Antwerpen P, Nève J. In vitro comparative assessment of the scavenging activity against three reactive oxygen species of non-steroidal anti-inflammatory drugs from the oxicam and sulfoanilide families. Eur J Pharmacol 2004; 496 (1-3): 55-61.
  13. Ferrari G.V, Natera J, Paulina Montaña M. Scavenging of photogenerated ROS by Oxicams. Possible biological and environmental implications. J Photochem Photobiol B 2015; 153: 233-9. doi: 10.1016/j.jphotobiol.2015.09.024
  14. Ozgocmen S, Ardicoglu O, Erdogan H et al. In vivo effect of celecoxib and tenoxicam on oxidant/anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci 2005; 35 (2): 137-43.
  15. Simpson J, Golding D.N, Freeman A.M et al. A large multicentre, parallel group, double-blind study comparing tenoxicam and piroxicam in the treatment of osteoarthritis and rheumatoid arthritis. Br J Clin Pract 1989; 43 (9): 328-33.
  16. Moser U, Waldburger H, Schwarz H.A, Gobelet C.A. A double-blindrandomisedmulticentre study with tenoxicam, piroxicam and diclofenac sodium retard in the treatment of ambulant patients with osteoarthritis and extra-articular rheumatism. Scand J Rheumatol Suppl 1989; 80: 71-80.
  17. Ejstrup L, Knudsen J.V, Petersen L. A randomised double-blind multicentre trial comparing tenoxicam and ketoprofen in osteoarthritis. Scand J Rheumatol Suppl 1989; 80: 48-53.
  18. Bellamy N, Buchanan W.W, Chalmers A et al. A multicenter study of tenoxicam and diclofenac in patients with osteoarthritis of the knee. J Rheumatol 1993; 20 (6): 999-1004.
  19. Riedemann P.J, Bersinic S, Cuddy L.J et al. A study to determine the efficacy and safety of tenoxicam versus piroxicam, diclofenac and indomethacin in patients with osteoarthritis: a meta-analysis. J Rheumatol 1993; 20 (12): 2095-103.
  20. Langdon C.G, Moran D.G, Jamieson V et al. A multicentre study of tenoxicam for the treatment of osteo-arthritis and rheumatoid arthritis in general practice. J Int Med Res 1990; 18 (6): 489-96.
  21. Kraag G.R, Gordon D.A, Ménard H.A et al. Patient compliance with tenoxicam in family practice. Clin Ther 1994; 16 (3): 581-93.
  22. Marcolongo R, Fioravanti A. Clinical experiences with tenoxicam. Preliminary results of a multicenter study. Recent Prog Med 1991; 82 (4): 242-9.
  23. Ibrahima K, Kodjo G, Issa S et al. Clinical efficacy and tolerability of tenoxicam in African patients with osteoarthritis, rheumatoid arthritis, tendinitis and/or bursitis: an open study. Curr Med Res Opin 1991; 12 (7): 471-8.
  24. Nived O, Sturfelt G, Eckernäs S.A, Singer P. A comparison of 6 months' compliance of patients with rheumatoid arthritis treated with tenoxicam and naproxen. Use of patient computer data to assess response to treatment. J Rheumatol 1994; 21 (8): 1537-41.
  25. Lund B, Andersen R.B, Fossgreen J et al. A long-term randomised trial on tenoxicam and piroxicam in osteoarthritis of the hip or knee: a 24-month interim report focusing on the 12-24 month interval. Eur J Rheumatol Inflamm 1987; 9 (2): 58-67.
  26. Lalos J, Tsachalos P, Gallis L. Long-term (four year) clinical trial with tenoxicam and basis therapy in patients suffering from rheumatoid arthritis. Scand J Rheumatol Suppl 1989; 80: 67-70.
  27. Perez-Ruiz F, Alonso-Ruiz A, Ansoleaga J.J. Comparative study of the efficacy and safety of aceclofenac and tenoxicam in rheumatoid arthritis. Clin Rheumatol 1996; 15 (5): 473-7.
  28. Villa Alcázar L.F, de Buergo M, Rico Lenza H, Montull Fruitós E. Aceclofenac is as safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on Aceclofenac in Ankylosing Spondylitis. J Rheumatol 1996; 23 (7): 1194-9.
  29. Valdés E.F. Use of tenoxicam in patients with acute gouty arthritis. Eur J Rheumatol Inflamm 1987; 9 (2): 133-6.
  30. Waterworth R.F, Waterworth S.M. An open assessment of tenoxicam (Tilcotil) in the treatment of acute gout in general practice. N Z Med J 1987; 100 (837): 744-5.
  31. Van Durme C.M, Wechalekar M.D, Buchbinder R et al. Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev 2014; 9: CD010120. doi: 10.1002/14651858.CD010120.pub2
  32. Szpalski M, Hayez J.P. Objective functional assessment of the efficacy of tenoxicam in the treatment of acute low back pain. A double-blind placebo-controlled study. Br J Rheumatol 1994; 33 (1): 74-8.
  33. Cheung L.K, Rodrigo C. Tenoxicam for pain relief following third molar surgery. Anesth Pain Control Dent 1992; 1 (4): 229-33.
  34. Zacharias M, De Silva R.K, Herbison P, Templer P. A randomized crossover trial of tenoxicam compared with rofecoxib for postoperative dental pain control. Anaesth Intensive Care 2004; 32 (6): 770-4.
  35. Arslan H, Topcuoglu H.S, Aladag H. Effectiveness of tenoxicam and ibuprofen for pain prevention following endodontic therapy in comparison to placebo: a randomized double-blind clinical trial. J Oral Sci 2011; 53 (2): 157-61.
  36. Ilhan O, Agacayak K.S, Gulsun B et al. A comparison of the effects of methylprednisolone and tenoxicam on pain, edema, and trismus after impacted lower third molar extraction. Med Sci Monit 2014; 20: 147-52. doi: 10.12659/MSM.890239
  37. Merry A.F, Swinburn P.F, Middleton N.G et al. Tenoxicam and paracetamol-codeine combination after oral surgery: a prospective, randomized, double-blind, placebo-controlled study. Br J Anaesth 1998; 81 (6): 875-80.
  38. Roelofse J.A, Van der Bijl P, Joubert J.J. Analgesic and anti-inflammatory efficacy of tenoxicam and diclofenac sodium after third molar surgery. Anesth Prog 1996; 43 (4): 103-7.
  39. Çebi A.T, Kasapoğlu M.B, Eren S, Kasapoğlu Ç. Comparison of the effects of diclofenac potassium and tenoxicam on postoperative pain, swelling, and trismus following third molar surgery. Turk J Med Sci 2018; 48 (2): 271-8. doi: 10.3906/sag-1702-100
  40. Kaplan V, Eroğlu C.N. Comparison of the Effects of Daily Single-Dose Use of Flurbiprofen, Diclofenac Sodium, and Tenoxicam on Postoperative Pain, Swelling, and Trismus: A Randomized Double-Blind Study. J Oral Maxillofac Surg 2016; 74 (10): 1946.e1-6. doi: 10.1016/j.joms.2016.05.015
  41. Cevik E, Cinar O, Salman N et al. Comparing the efficacy of intravenous tenoxicam, lornoxicam, and dexketoprofen trometamol for the treatment of renal colic. Am J Emerg Med 2012; 30 (8): 1486-90. doi: 10.1016/j.ajem.2011.12.010
  42. Kekeç Z, Yilmaz U, Sözüer E. The effectiveness of tenoxicam vs isosorbide dinitrate plus tenoxicam in the treatment of acute renal colic. BJU Int 2000; 85 (7): 783-5.
  43. Al-Waili N.S, Saloom K.Y. Intravenous tenoxicam to treat acute renal colic: comparison with buscopancompositum. J Pak Med Assoc 1998; 48 (12): 370-2.
  44. Al-Waili N.S. Intramuscular tenoxicam to treat acute renal colic. Br J Urol 1996; 77 (1): 15-6.
  45. Masudi T, Capitelli-McMahon H, Anwar S. Acute pain management in symptomatic cholelithiasis. World J Gastrointest Surg 2016; 8 (10): 713-8.
  46. Chang W.K, Wu H.L, Yang C.S et al. Effect on pain relief and inflammatory response following addition of tenoxicam to intravenous patient-controlled morphine analgesia: a double-blind, randomized, controlled study in patients undergoing spine fusion surgery. Pain Med 2013; 14 (5): 736-48. doi: 10.1111/pme.12067
  47. Gunusen I, Karaman S, Acar A et al. The efficacy of paracetamol versus tenoxicam on postoperative pain and morphine consumption after abdominal hysterectomy: a placebo-controlled, randomized study. Clin Exp Obstet Gynecol 2012; 39 (1): 49-52.
  48. Munro F.J, Young S.J, Broome I.J et al. Intravenous tenoxicam for analgesia following laparoscopic cholecystectomy. Anaesth Intensive Care 1998; 26 (1): 56-60.
  49. Akca T, Colak T, Kanik A et al. The effect of preoperative intravenous use of tenoxicam: a prospective, double-blind, placebo-controlled study. J Invest Surg 2004; 17 (6): 333-8.
  50. Merry A.F, Sidebotham D.A, Middleton N.G et al. Tenoxicam 20 mg or 40 mg after thoracotomy: a prospective, randomized, double-blind, placebo-controlled study. Anaesth Intensive Care 2002; 30 (2): 160-6.
  51. Papathanassiou N.P. Intra-articular use of tenoxicam in degenerative osteoarthritis of the knee joint. J Int Med Res 1994; 22 (6): 332-7.
  52. Unlu Z, Ay K, Tuzun C. Comparison of intra-articular tenoxicam and oral tenoxicam for pain and physical functioning in osteoarthritis of the knee. Clin Rheumatol 2006; 25 (1): 54-61.
  53. Erbas M, Simsek T, Kiraz H.A et al. Comparison of the effectivity of oral and intra-articular administration of tenoxicam in patients with knee osteoarthritis. Braz J Anesthesiol 2015; 65 (5): 333-7. doi: 10.1016/j.bjane.2013.12.003
  54. Çift H, Özkan.FÜ, Tolu S et al. Comparison of subacromial tenoxicam and steroid injections in the treatment of impingement syndrome. Eklem Hastalik Cerrahisi 2015; 26 (1): 16-20. doi: 10.5606/ehc.2015.05
  55. Guner S, Onder H, Guner S.I et al. Effectiveness of local tenoxicam versus corticosteroid injection for plantar fasciitis treatment. Orthopedics 2013; 36 (10): e1322-6. doi: 10.3928/01477447-20130920-27
  56. Cook T.M, Tuckey J.P, Nolan J.P. Analgesia after day-case knee arthroscopy: double-blind study of intra-articular tenoxicam, intra-articular bupivacaine and placebo. Br J Anaesth 1997; 78 (2): 163-8.
  57. Talu G.K, Ozyalçin S, Koltka K et al. Comparison of efficacy of intraarticular application of tenoxicam, bupivacaine and tenoxicam: bupivacaine combination in arthroscopic knee surgery. Knee Surg Sports Traumatol Arthrosc 2002; 10 (6): 355-60.
  58. Oral E.G, Hanci A, Ulufer Sivrikaya G et al. The Analgesic Effects of Morphine and Tramadol Added to Intra-articular Levobupivacaine-Tenoxicam Combination for Arthroscopic Knee Surgery on Postoperative Pain; a Randomized Clinical Trial. Anesth Pain Med 2015; 5 (3): e24047. doi: 10.5812/aapm.5(3)2015.24047
  59. Jawish R, Najdi H, Abi Safi C, Chameseddine A. The effect of intra-articular Tenoxicam on knee effusion after arthroscopy. Int Orthop 2015; 39 (7): 1423-6. doi: 10.1007/s00264-014-2640-3
  60. Sanel S, Arpaz O, Unay K et al. Comparison of intra-articular bupivacaine-morphine with bupivacaine-tenoxicam combinations on post-operative analgesia in patients with arthroscopic meniscectomy: a prospective, randomised study. Int Orthop 2016; 40 (3): 601-5. doi: 10.1007/s00264-015-2990-5
  61. Castellsague J, Riera-Guardia N, Calingaert B et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf 2012; 35 (12): 1127-46. doi: 10.2165/11633470-000000000-00000
  62. Müller P, Dammann H.G, Marinis E, Simon B. Gastroduodenal tolerance of tenoxicam versus diclofenac-Na: an endoscopy double-blind controlled study in healthy probands. Z Rheumatol 1989; 48 (5): 243-5.
  63. Al-Quorain A.A, Satti M.B, Marwah S et al. Non-steroidal anti-inflammatory drug-induced gastropathy: a comparative endoscopic and histopathological evaluation of the effects of tenoxicam and diclofenac. J Int Med Res 1993; 21 (2): 89-97.
  64. Perpignano G, Bogliolo A, Puccetti L. Double-blind comparison of the efficacy and safety of etodolac SR 600 mg u.i.d. and of tenoxicam 20 mg u.i.d. in elderly patients with osteoarthritis of the hip and of the knee. Int J Clin Pharmacol Res 1994; 14 (5-6): 203-16.
  65. Lapeyre-Mestre M, Grolleau S, Montastruc J.L. Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002-2006. Fundam Clin Pharmacol 2013; 27 (2): 223-30. doi: 10.1111/j.1472-8206.2011.00991.x
  66. McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006; 296 (13): 1633-44.
  67. Varas-Lorenzo С, Riera-Guardia N, Calingaert B et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiology Drug Safety 2013; 22: 559-70.
  68. Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology 2015; 23 (1): 1-16.
  69. Arfè A, Scotti L, Varas-Lorenzo C et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ 2016; 354: i4857. doi: 10.1136/bmj.i4857
  70. Каратеев А.Е. Теноксикам. Клин. фармакология и терапия. 2017; 26 (5): 44-50.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».